NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
NICE
NICE accelerates breakthrough framework for complex liver diseases
NICE drives innovation, reshaping MASH evaluations with transformative guidance.
Focus Brief: Market Access Weekly September 1 to 7, 2025
Global market access shifts: HTA speed, UK pricing, digital disruption.
NICE Guidance Catalyzes Digital Mental Health Innovation
NICE empowers NHS with digital health tech for children’s mental health, boosting access and efficiency.
Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.